Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study

Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study Publisher Pubmed

Emamzadehfard S¹ ; Kamaloo A¹ ; Paydary K¹ ; Ahmadipour A¹ ; Zeinoddini A¹ ; Ghaleiha A² ; Mohammadinejad P¹ ; Zeinoddini A¹ ; Akhondzadeh S¹

Show Affiliations

1. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Behavioral Disorders and Substance Abuse Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

Source: Psychiatry and Clinical Neurosciences Published:2016

Abstract

Aim: The aim of the present randomized, double-blind, placebo-controlled, 8-week trial was to assess the efficacy and tolerability of riluzole augmentation of fluvoxamine in treatment of patients with moderate to severe obsessive–compulsive disorder. Methods: Patients were randomized into two parallel groups to receive fluvoxamine plus placebo or fluvoxamine plus riluzole (50 mg twice daily). All patients, regardless of their treatment group, received fluvoxamine at 100 mg/day for the initial 4 weeks of the study followed by 200 mg/day of fluvoxamine for the rest of the trial course. A total of 50 patients (25 in each group) were evaluated for response to treatment using the Yale–Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and at weeks 4, 8 and 10. Side-effects were recorded using predesigned checklists in each visit. Repeated-measure analysis of variance showed a significant effect for time × treatment interaction in the Y-BOCS total score and a significant effect for time × treatment interaction in the Y-BOCS Compulsive subscale score between the two groups. Results: Repeated-measure analysis of variance showed a significant effect for time × treatment interaction (Greenhouse–Geisser corrected: F = 4.07, d.f. = 1.22, P = 0.04) in the Y-BOCS total score and a significant effect for time × treatment interaction (Greenhouse–Geisser corrected: F = 4.45, d.f. = 1.33, P = 0.028) in the Y-BOCS Compulsive subscale score between the two groups. Riluzole augmentation therapy demonstrated higher, partial or complete treatment response according to the Y-BOCS total scores. Conclusion: Riluzole may be of clinical use as an adjuvant agent to fluvoxamine in treatment of moderate to severe obsessive–compulsive disorder. © 2016 The Authors. Psychiatry and Clinical Neurosciences © 2016 Japanese Society of Psychiatry and Neurology

Related Docs

View other Related Docs

1. Minocycline Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2016)

2. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)

3. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)

4. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)

5. N-Acetylcysteine Augmentation Therapy for Moderate-To-Severe Obsessive-Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Pharmacy and Therapeutics (2016)

6. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial, Pharmacopsychiatry (2018)

7. Correlations Between Single Nucleotide Polymorphisms in Obsessive-Compulsive Disorder With the Clinical Features or Response to Therapy, Journal of Psychiatric Research (2023)

8. A Systematic Review and Meta-Analysis: Memantine Augmentation in Moderate to Severe Obsessive-Compulsive Disorder, Psychiatry Research (2019)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (17)

Farzin Rezaei (4)

Style	Citing Format
MLA	Emamzadehfard S, et al.. "Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study." Psychiatry and Clinical Neurosciences, vol. 70, no. 8, 2016, pp. 332-341.
APA	Emamzadehfard S, Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S (2016). Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study. Psychiatry and Clinical Neurosciences, 70(8), 332-341.
Chicago	Emamzadehfard S, Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. "Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study." Psychiatry and Clinical Neurosciences 70, no. 8 (2016): 332-341.
Harvard	Emamzadehfard S et al. (2016) 'Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study', Psychiatry and Clinical Neurosciences, 70(8), pp. 332-341.
Vancouver	Emamzadehfard S, Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, et al.. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study. Psychiatry and Clinical Neurosciences. 2016;70(8):332-341.
BibTex	@article{ author = {Emamzadehfard S and Kamaloo A and Paydary K and Ahmadipour A and Zeinoddini A and Ghaleiha A and Mohammadinejad P and Zeinoddini A and Akhondzadeh S}, title = {Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study}, journal = {Psychiatry and Clinical Neurosciences}, volume = {70}, number = {8}, pages = {332-341}, year = {2016} }
RIS	TY - JOUR AU - Emamzadehfard S AU - Kamaloo A AU - Paydary K AU - Ahmadipour A AU - Zeinoddini A AU - Ghaleiha A AU - Mohammadinejad P AU - Zeinoddini A AU - Akhondzadeh S TI - Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study JO - Psychiatry and Clinical Neurosciences VL - 70 IS - 8 SP - 332 EP - 341 PY - 2016 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract